BioXcel Therapeutics(BTAI) - 2023 Q4 - Annual Results

Exhibit 99.1 Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Conference call and webcast set for 8:00 a.m. ET today "We believe our late-stage programs evaluating BXCL501 for acute agitation associated with Alzheimer's dementia, bipolar disorders, and schizophrenia represent groundbreaking opportunities to bring much-needed treatment options to large numbers of patients and caregivers," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. "We are pleased ...